hsa-miR-106b-5p participates in the development of chronic thromboembolic pulmonary hypertension via targeting matrix metalloproteinase 2.

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by elevated pressure in pulmonary arteries. This study was performed to explore the critical miRNAs and genes affecting the pathogenesis of CTEPH.
METHODS: GSE56914 dataset (10 CTEPH whole blood samples and 10 control samples) was downloaded from the Gene Expression Omnibus database. Using limma package, the differentially expressed miRNAs (DE-miRNAs) were acquired. After miRNA-target pairs were obtained using miRWalk2.0 tool, a miRNA-target regulatory network was built by Cytoscape software. Using DAVID tool, significantly enriched pathways involving the target genes were identified. Moreover, the protein-protein interaction network and transcription factor-target regulatory network were built by the Cytoscape software. Additionally, quantitative real-time PCR (qRT-PCR) experiments and luciferase assay were conducted to validate miRNA/gene expression and miRNA-target regulatory relationship, respectively.
RESULTS: There were 25 DE-miRNAs (8 up-regulated and 17 down-regulated) between CTEPH and control groups. The target genes of has-let-7b-3p, has-miR-17-5p, has-miR-3202, has-miR-106b-5p, and has-miR-665 were enriched in multiple pathways such as "Insulin secretion". qRT-PCR analysis confirmed upregulation of hsa-miR-3202, hsa-miR-665, and matrix metalloproteinase 2 (MMP2) as well as downregulation of hsa-let-7b-3p, hsa-miR-17-5p, and hsa-miR-106b-5p. Luciferase assay indicated that MMP2 was negatively mediated by hsa-miR-106b-5p.
CONCLUSIONS: These miRNAs and genes were associated with the pathogenesis of CTEPH. Besides, hsa-miR-106b-5p was involved in the development of CTEPH via targeting MMP2.

Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH), as a fourth category of pulmonary hypertension (PH), refers to the elevated pressure in pulmonary arteries, which is induced by stenosis or persistent occlusion of pulmonary arteries.[1,2] CTEPH is the result of incomplete thrombolysis of an acute pulmonary embolism that progressively develops into fibrosis.[3] The symptoms of early CTEPH are usually absent or non-specific, and advanced CTEPH is only correlated with right heart failure.[4] Therefore, CTEPH is hard to be diagnosed at an early stage. Early and accurate diagnosis is important for successful treatment since the outcome of CTEPH patients without timely treatment is usually unfavorable, with a lower than 40% five-year survival rate.[5] Thus, the underlying mechanisms of CTEPH should be strongly investigated to offer effective biomarkers or targets for CTEPH diagnosis or treatment.

In recent years, genes or miRNAs involved in CTEPH have been gradually investigated. Satoh et al. have revealed that chronic hypoxia can cause a significant increase in thrombin-activatable fibrinolysis inhibitor and thrombin and thrombomodulin plasma levels, which are associated with thrombus formation in patients with CTEPH.[6] In addition, down-regulated let-7d in CTEPH patients can enhance proliferation of pulmonary artery smooth muscle cells (PASMCs), which may be correlated with the development and progression of CTEPH.[7,8] Moreover, miR-664a, miR-382, miR-150, miR-337, miR-127, and miR-376c have been found to be abnormally expressed in serum microvesicles of CTEPH patients compared to normal controls.[9] Nevertheless, there are still many miRNAs and genes implicated in the pathogenesis of CTEPH that have not been reported.

In 2014, Guo et al. analyzed the dysregulation of miRNAs in plasma samples from healthy controls and CTEPH patients and explored their underlying functions. They discovered an abnormal miRNA signature in CTEPH patients and that decreased levels of let-7b may play a role in CTEPH via affecting endothelin-1 expression, and the function of PASMCs and pulmonary arterial endothelial cells.[10] However, they have not explored the key miRNAs involved in CTEPH using comprehensive bioinformatics methods. In this study, multiple bioinformatics analyses were conducted to screen key miRNAs and genes affecting the pathogenesis of CTEPH. Quantitative real-time PCR (qRT-PCR) experiments and luciferase assay were performed to confirm the results of the bioinformatics analysis. Our findings might provide novel targets for the therapy or diagnosis of CTEPH.

Methods

Data source

The microarray dataset GSE56914 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56914; species: Homo sapiens; platform: GPL18587 miRCURY LNA™ microRNA Arrays (v14.0) was downloaded from the Gene Expression Omnibus (GEO) database. In GSE56914, there were 10 whole blood samples from CTEPH patients and 10 whole blood samples from healthy controls. CTEPH was diagnosed using a previously described protocol.[11] Patients with other cardiovascular diseases and malignancies who had undergone treatment for PH except for anticoagulation were excluded from the study. Whole blood samples were collected and centrifuged at 1000 g for 10 min to isolate plasma.[10] This study analyzed the microarray dataset uploaded by Guo et al.,[10] therefore, ethical review and informed consent were not needed.

Data treatment and differential expression analysis

For the matrix data, expression background correction and standardization pretreatment were performed using the R package limma[12] (http://www.bioconductor.org/packages/2.9/bioc/html/limma.html, version 3.10.3).

The miRNA expression matrixes were divided into CTEPH and control groups to screen differentially expressed miRNAs (DE-miRNAs) between the two. Differences were analyzed for significance by the unpaired T test method in limma package.[12] The DE-miRNAs were required to have a |log fold change (FC)| > 1 and p value < 0.05.

Prediction of miRNA-target pairs

The top 10 DE-miRNAs (up-regulated or down-regulated) with higher |log FC| values were considered as key DE-miRNAs for further analysis. Using miRWalk2.0 tool (p value < 0.05, seed length ≥ 7, input parameter: 3’UTR, http://zmf.umm.uni-heidelberg.de/mirwalk2),[13] target genes of the key DE-miRNAs were predicted. The miRNA-target pairs included in six or more databases of miRWalk, miRanda, mirbridge, miRDB, miRMap, RNA22, Targetscan databases were selected. Using Cytoscape software[14] (http://www.cytoscape.org/, version: 3.2.0), a regulatory network was constructed.

Pathway enrichment analysis and building of miRNA-target regulatory network

Since there were too many miRNA-target pairs, the targets corresponding to the miRNAs with the highest degrees were selected for Kyoto Encyclopedia of Genes and Genomes[15] (KEGG) analysis. Under the significant threshold of p value < 0.05, KEGG analysis was executed using DAVID tool[16] (https://david.ncifcrf.gov/, version 6.8).

To better demonstrate the structure of the regulatory network, the target genes with degree = 1 in the above regulatory network were removed. For the remaining target genes, a regulatory network was built by the Cytoscape software.[14]

Construction of protein–protein interaction (PPI) network and network module

Combined with STRING database (http://string-db.org/, version 10.0),[17] PPI pairs were predicted for the target genes in the regulatory network, and PPI score was defined as 0.7. Afterwards, the PPI network for the target genes was built based on Cytoscape software.[14] The degree centrality was used to analyze the scores of the network nodes. Higher node score indicated that the location of the network node was more important. Moreover, the MCODE plug-in (http://apps.cytoscape.org/apps/MCODE, version 1.4.2) in Cytoscape software[14] was used to analyze the significant network modules, with a score ≥5 as a threshold. In addition, the module nodes were constructed with the Gene Ontology (GO)_biological process (BP)[18] enrichment analysis using DAVID tool.[16]

Prediction of transcription factor (TF)-target pairs

Based on WebGestalt GAST tool[19] (http://www.webgestalt.org/option.php), TFs targeting the genes implicated in the PPI network were predicted through overrepresentation enrichment analysis. The enrichment parameter was set as number of enriched genes ≥2.

qRT-PCR analysis

qRT-PCR experiments were performed in a total of eight whole blood samples from CTEPH patients and eight whole blood samples from healthy controls were obtained from Beijing Chao-Yang Hospital, Capital Medical University. This study’s protocol was approved by the Ethics Committee of Beijing Chao-Yang Hospital, Capital Medical University. The requirement to obtain informed written consent was waived. Using Primer Premier 6.0 software (Premier Software Inc., Cherry Hill, NJ), the primer sequences of hsa-let-7b-3p, hsa-miR-17-5p, hsa-miR-3202, hsa-miR-106b-5p, and hsa-miR-665, as well as hsa-miR-106b-5p target genes bone morphogenetic protein receptor 2 (BMPR2), forkhead box J2 (FOXJ2), and matrix metalloproteinase 2 (MMP2) were designed (Table S1). The primer sequences were produced by Sangon Biotech Co., Ltd (Shanghai, CHN). After performing a reverse transcription reaction, qRT-PCR experiments were conducted using SYBR Green master mix kit (Applied Biosystems, Foster City, CA). The 20 µl amplification reaction included: 1 µl forward primer, and 1 µl reverse primer, 8 µl cDNA template (at a constant concentration), and 10 µl SYBR Premix Ex Taq (2×). The reaction conditions were: 50℃ for 3 min; 95℃ for 3 min; 95℃ for 10 s, and 40 cycles at 60℃ for 30 s; melt curve 60–95℃: increment 0.5℃ for 10 s plate read. All experiments were conducted three times to ensure accuracy.

Luciferase assay

Based on the results of qRT-PCR experiments, hsa-miR-106b-5p/MMP2 pair was selected for performing luciferase assays. The MMP2 3’UTR fragments containing the putative or mutated binding site of hsa-miR-106b-5p were synthesized and inserted into the downstream of luciferase coding sequence in pUC57-Amp vector. Then, the recombinant product was transformed into TOP10 competent cells (Invitrogen, Carlsbad, CA). Single colonies were cultured and plasmids were extracted using Plasmid Extraction Kit (Tiangen, Shanghai, China) based on the manufacturer’s instructions. pUC57-MMP2 3’UTR plasmids and pmir-GLO vector were cut with NheI and XbaI restriction enzymes and then ligated. Subsequently, the recombinant product was transformed into stbl3 competent cells (Invitrogen). After plasmid extraction, identification by enzyme digestion, and sequencing were conducted, positive clones were cultured and plasmids were extracted in large quantities.

The 293T cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in Dulbecco’s modified eagle medium (DMEM; Gibco, Grand Island, NY) containing 1% penicillin–streptomycin (Gibco), and 10% fetal bovine serum (Gibco). At the logarithmic growth phase, 293T cells were washed with phosphate buffer solution (PBS) once, digested by 0.05% pancreatin at 37℃ for 1 min, and centrifuged at 300 g for 3 min. The cells were then counted and cultured in a 12-well plate (1.5 × 105 cells/well) overnight at 37℃. The cells were randomly divided into Luc-NC + miR-106b-5p mimics, Luc-MMP2 3’UTR (WT) + miR-106b-5p mimics, Luc-MMP2 3’UTR (WT) + miR-NC, Luc-MMP2 3’UTR (MUT) + miR-106b-5p mimics, Luc-MMP2 3’UTR (MUT) + miR-NC, Luc-NC + miR-NC. The plasmids and miR-106b-5p mimic were added into 300 μl opt-MEM medium (Invitrogen) in a 1:1 ratio (1 µg plasmids: 20 pM siRNA, tube A). Meanwhile, 2 μl lipofectamine 2000 was dissolved in 300 μl opt-MEM medium (tube B). A and B tubes were incubated for 5 min at room temperature, then mixed (tube C) and incubated for another 20 min. The media in the 12-well plate were replaced by opt-MEM medium (800 μl/well), and the mixture in tube C was added into the corresponding well. After performing transfection for 4–6 h, FAM-NC fluorescence intensity was observed under fluorescence microscope, and the medium was replaced with DMEM.

Fluorescence intensity of the overexpressed GFP was observed and photographed under a fluorescence microscope 48 h after transfection. Then, the cells were washed with PBS, lysed with lysis buffer (200 μl/well) for 30 min, and centrifuged at 12,000 g at 4℃ for 10 min. The dual-luciferase assay kit (Beyotime, Nantong, China) and a multimode reader (BioTek, Winooski, VT) were used to detect firefly and Renilla luciferases.

Statistical analysis

Combined with the 2−ΔΔCt method,[20] the expression values of the key miRNAs and genes were calculated. Statistical analysis of the experimental data was conducted using SPSS 16.0 software (SPSS Inc., Chicago, IL). All data were presented as mean ± standard deviation. The one-way analysis of variance[21] was utilized for comparisons between groups. The p < 0.05 and p < 0.01 indicated a significant difference and a highly significant difference, respectively.

Results

Differential expression analysis

Following initial data analysis, 898 miRNAs were identified from the raw data. According to the selection criteria, 25 DE-miRNAs between CTEPH and control groups were analyzed, including eight up-regulated miRNAs (such as hsa-miR-3202 and hsa-miR-665) and 17 down-regulated miRNAs (such as hsa-miR-106b, hsa-let-7b, hsa-miR-17, hsa-miR-93, and hsa-miR-20a; Table S2).

Pathway enrichment analysis and miRNA-target regulatory network analysis

Through limiting miRNAs and the number of target genes, 2269 miRNA-target pairs (involving 2 up-regulated miRNAs, 13 down-regulated miRNAs, and 756 target genes) were finally obtained. Based on the 2269 miRNA-target pairs (including hsa-miR-106b-5p → BMPR2, hsa-miR-106b-5p → FOXJ2, and hsa-miR-106b-5p → MMP2), the miRNA-target regulatory network was constructed (Fig. 1a).

Fig. 1.

The miRNA-target regulatory network. Red triangles, green arrows, and blue circles represent up-regulated miRNAs, down-regulated miRNAs, and target genes, respectively (a); the protein–protein interaction network. Red circles and green diamonds represent the target genes of up-regulated miRNAs and down-regulated miRNAs, respectively. The higher the degree of a node, the larger the node is (b). The modules (a), (b), (c), and (d) identified from the protein–protein interaction network. Red circles and green diamonds represent the target genes of up-regulated miRNAs and down-regulated miRNAs, respectively. The higher the degree of a node, the larger the node is (c). The transcription factor (TF)-target regulatory network. Red circles and green diamonds represent the target genes of up-regulated miRNAs and down-regulated miRNAs, respectively. Orange hexagons stand for TFs. The higher the degree of a node, the larger the node is (d).

Pathway enrichment analysis was conducted for the target genes of the top 15 miRNAs (listed by degree values) in the miRNA-target regulatory network. As a result, the top 10 pathways for the targets of the up-regulated has-miR-665 (such as Hippo signaling pathway) and has-miR-3202 (such as Insulin secretion) are listed in Table 1a. Meanwhile, the top five pathways for the targets of the down-regulated has-miR-17-5p (such as chronic myeloid leukemia), has-miR-93-5p (such as chronic myeloid leukemia), has-miR-20a-5p (such as TGF-beta signaling pathway), has-miR-106b-5p (such as MAPK signaling pathway and pathways in cancer), has-miR-320a (such as signaling pathways regulating pluripotency of stem cells), has-miR-16-5p (such as ubiquitin-mediated proteolysis), has-miR-30c-5p (such as axon guidance), has-let-7b-3p (such as adherens junction), has-miR-17-3p (such as oxytocin signaling pathway), has-miR-22-3p (such as insulin resistance), has-miR-22-5p (such as Hippo signaling pathway), has-let-7b-5p (such as signaling pathways regulating pluripotency of stem cells), and has-miR-20a-3p (such as adherens junction) are listed in Table 1b.

Table 1.

The pathways enriched for the target genes of the top 15 miRNAs in the miRNA-target regulatory network. (a) The pathways enriched for the target genes of the up-regulated miRNAs (top 10 listed); (b) the pathways enriched for the target genes of the down-regulated miRNAs (top 5 listed).

miRNA	ID	Name	Count	p value
(a)
has-miR-665	hsa04390	Hippo signaling pathway	10	2.31E − 03
	hsa04022	cGMP-PKG signaling pathway	9	1.39E − 02
	hsa04020	Calcium signaling pathway	9	2.09E − 02
	hsa04014	Ras signaling pathway	10	2.86E − 02
	hsa05212	Pancreatic cancer	5	3.52E − 02
	hsa05200	Pathways in cancer	14	3.67E − 02
	hsa05205	Proteoglycans in cancer	9	3.72E − 02
	hsa04115	p53 signaling pathway	5	3.87E − 02
	hsa04917	Prolactin signaling pathway	5	4.63E − 02
	hsa04520	Adherens junction	5	4.63E − 02
has-miR-3202	hsa05214	Glioma	5	5.01E − 03
	hsa05206	MicroRNAs in cancer	9	1.08E − 02
	hsa04151	PI3K-Akt signaling pathway	10	1.09E − 02
	hsa04911	Insulin secretion	5	1.28E − 02
	hsa05215	Prostate cancer	5	1.44E − 02
	hsa04024	cAMP signaling pathway	7	1.89E − 02
	hsa05161	Hepatitis B	6	1.92E − 02
	hsa04261	Adrenergic signaling in cardiomyocytes	6	1.97E − 02
	hsa05223	Non-small cell lung cancer	4	2.18E − 02
	hsa04022	cGMP-PKG signaling pathway	6	3.21E − 02
(b)
has-miR-17-5p	hsa05220	Chronic myeloid leukemia	8	1.73E − 03
	hsa05214	Glioma	7	4.77E − 03
	hsa05160	Hepatitis C	10	4.95E − 03
	hsa04012	ErbB signaling pathway	8	5.06E − 03
	hsa05218	Melanoma	7	7.34E − 03
has-miR-93-5p	hsa05220	Chronic myeloid leukemia	8	1.26E − 03
	hsa05160	Hepatitis C	10	3.44E − 03
	hsa05200	Pathways in cancer	19	3.85E − 03
	hsa05166	HTLV-I infection	14	5.93E − 03
	hsa04360	Axon guidance	9	8.74E − 03
has-miR-20a-5p	hsa04350	TGF-beta signaling pathway	7	1.15E − 02
	hsa04310	Wnt signaling pathway	9	1.26E − 02
	hsa04360	Axon guidance	8	2.45E − 02
	hsa05166	HTLV-I infection	12	2.98E − 02
	hsa05200	Pathways in cancer	16	3.14E − 02
has-miR-106b-5p	hsa04010	MAPK signaling pathway	13	8.35E − 03
	hsa05200	Pathways in cancer	16	2.07E − 02
	hsa04310	Wnt signaling pathway	8	2.83E − 02
has-miR-320a	hsa04550	Signaling pathways regulating pluripotency of stem cells	7	1.01E − 02
	hsa05211	Renal cell carcinoma	5	1.03E − 02
	hsa05203	Viral carcinogenesis	8	1.81E − 02
	hsa05215	Prostate cancer	5	2.84E − 02
has-miR-16-5p	hsa04120	Ubiquitin-mediated proteolysis	7	3.34E − 03
	hsa04070	Phosphatidylinositol signaling system	6	3.85E − 03
	hsa04115	p53 signaling pathway	4	3.47E − 02
has-miR-30c-5p	hsa04360	Axon guidance	5	2.54E − 02
	hsa04710	Circadian rhythm	3	3.03E − 02
has-let-7b-3p	hsa04520	Adherens junction	4	1.02E − 02
	hsa05200	Pathways in cancer	8	1.13E − 02
	hsa04024	cAMP signaling pathway	5	3.64E − 02
has-miR-17-3p	hsa04921	Oxytocin signaling pathway	5	9.66E − 03
has-miR-22-3p	hsa04931	Insulin resistance	5	6.97E − 03
	hsa04144	Endocytosis	6	3.49E − 02
	hsa00510	N-Glycan biosynthesis	3	4.69E − 02
has-miR-22-5p	hsa04390	Hippo signaling pathway	4	4.63E − 02
	hsa05205	Proteoglycans in cancer	7	2.43E − 03
	hsa04916	Melanogenesis	5	4.93E − 03
	hsa05206	MicroRNAs in cancer	7	1.33E − 02
	hsa04390	Hippo signaling pathway	5	2.03E − 02
has-let-7b-5p	hsa04550	Signaling pathways regulating pluripotency of stem cells	7	3.79E − 04
	hsa05205	Proteoglycans in cancer	7	2.43E − 03
	hsa04916	Melanogenesis	5	4.93E − 03
	hsa05206	MicroRNAs in cancer	7	1.33E − 02
	hsa04390	Hippo signaling pathway	5	2.03E − 02
has-miR-20a-3p	hsa04520	Adherens junction	4	8.38E − 03

Building of PPI network and network module

Using targets in the miRNA-target network, a PPI network (involving 349 nodes and 751 edges) was built (Fig. 1b). From the PPI network, four significant modules (module A, score = 16, involving 120 edges and 16 nodes; module B, score = 7.6, involving 38 edges and 11 nodes; module C, score = 5.818, involving 32 edges and 12 nodes; module D, score = 5.818, involving 32 edges and 12 nodes) were screened (Fig. 1c).

For the genes included in each module, GO_BP enrichment analysis was conducted. The top 5 GO_BP terms for the nodes in module A (such as protein polyubiquitination), B (such as inflammatory response), C (such as regulation of lipid kinase activity), and D (such as retrograde transport, endosome to Golgi) are listed in Table 2.

Table 2.

The Gene Ontology (GO)_biological process (BP) terms enriched for the nodes in module A, B, C, and D (top 5 listed).

Module	ID	Name	Count	p value	Genes
Module A	GO:0000209	Protein polyubiquitination	8	5.44E − 11	MKRN1, FBXW7, TRIM36, HECTD2, UBE3C, UBE2B, FBXW11, UNKL
	GO:0016567	Protein ubiquitination	8	5.81E − 09	FBXW7, FBXO40, KBTBD8, FBXL5, ASB1, UBE2B, FBXW11, KLHL2
	GO:0031146	SCF-dependent proteasomal ubiquitin-dependent protein catabolic process	3	1.76E − 04	FBXW7, FBXL5, FBXW11
	GO:0042787	Protein ubiquitination involved in ubiquitin-dependent protein catabolic process	3	6.99E − 03	HECTD2, UBE3C, TCEB1
	GO:0070936	Protein K48-linked ubiquitination	2	3.85E − 02	UBE2Q2, UBE2B
Module B	GO:0006954	Inflammatory response	5	2.94E − 05	S1PR3, AGTR2, HRH4, CXCL6, F2R
	GO:0007186	G-protein coupled receptor signaling pathway	5	8.28E − 04	S1PR3, AGTR2, GPR132, CXCL6, F2R
	GO:0032651	Regulation of interleukin-1 beta production	2	1.61E − 03	S1PR3, F2R
	GO:0030168	Platelet activation	3	1.62E − 03	F2RL2, PIK3R1, F2R
	GO:0007204	Positive regulation of cytosolic calcium ion concentration	3	2.19E − 03	S1PR3, HRH4, F2R
Module C	GO:0043550	Regulation of lipid kinase activity	3	3.90E − 06	RBL2, RBL1, RB1
	GO:0000082	G1/S transition of mitotic cell cycle	4	3.47E − 05	CDKN1A, CDK6, PPP3CA, RB1
	GO:0051726	Regulation of cell cycle	4	6.21E − 05	E2F5, RBL2, RBL1, RB1
	GO:0006470	Protein dephosphorylation	4	6.51E − 05	PPP2R3A, PPP3R1, PPP3CA, PPP2R2A
	GO:0010629	Negative regulation of gene expression	4	8.36E − 05	CDKN1A, RBL2, RBL1, RB1
Module D	GO:0042147	Retrograde transport, endosome to Golgi	3	8.94E − 04	STX16, VPS53, GCC2
	GO:0090161	Golgi ribbon formation	2	7.18E − 03	STX16, GCC2
	GO:0000042	Protein targeting to Golgi	2	1.30E − 02	GOLGA1, GCC2

Construction of TF-target regulatory network

Among the top 10 predicted results, six known TFs predicted for the genes in the PPI network. The TF-target regulatory network was comprised of 187 TF-target pairs, and 134 nodes (involving 6 TFs, 2 targets of up-regulated miRNAs, and 126 targets of down-regulated miRNAs; Fig. 1d).

In comparison to control group, hsa-let-7b-3p, hsa-miR-106b-5p, and hsa-miR-17-5p were significantly down-regulated, and hsa-miR-665 and hsa-miR-3202 were significantly up-regulated in the CTEPH group (p < 0.05, Fig. 2). Besides, the expression levels of hsa-miR-106b-5p targets BMPR2, FOXJ2 and MMP2 were also measured. The results showed that the expression levels of BMPR2 and FOXJ2 were not significantly changed, while the expression of MMP2 was significantly down-regulated in the CTEPH group compared to the control group (p < 0.05, Fig. S1).

Fig. 2.

The relative expression of hsa-let-7b-3p (a), hsa-miR-106b-5p (b), hsa-miR-17-5p (c), hsa-miR-665 (d), and hsa-miR-3202 (e). CTEPH: chronic thromboembolic pulmonary hypertension. *Indicates p < 0.05 and **indicates p < 0.01.

The luciferase ratio in wide-type Luc-MMP2 3’UTR + miR-106b-5p mimics group was significantly reduced in comparison to other five groups (Luc-NC + miR-106b-5p mimics, wide-type Luc-MMP2 3’UTR + miR-NC, Luc-NC + miR-NC, mutant MMP2 3’UTR + miR-NC and mutant MMP2 3’UTR + miR-106b-5p mimics groups (p < 0.01, Fig. S2). However, no significant changes of luciferase activity were identified in these five groups. The inhibitory effect of luciferase ratio was recovered in mutant MMP2 3’UTR + miR-NC and mutant MMP2 3’UTR + miR-106b-5p mimics groups than wide-type Luc-MMP2 3’UTR + miR-106b-5p mimics group (Fig. S2).

Discussion

A total of 25 DE-miRNAs (8 up-regulated (e.g., hsa-miR-665 and hsa-miR-3202) and 17 down-regulated (e.g., hsa-let-7b-3p, hsa-miR-106b-5p, and hsa-miR-17-5p)) between CTEPH and control groups were identified by differential expression analysis. In agreement with the bioinformatic prediction, the upregulation of hsa-miR-665 and hsa-miR-3202, and downregulation of hsa-let-7b-3p, hsa-miR-106b-5p, and hsa-miR-17-5p were also detected in eight CTEPH samples through qRT-PCR analysis. Several pathways were enriched for the genes targeted by has-miR-3202 (such as insulin resistance). In addition, the result of the luciferase assay showed that hsa-miR-106b-5p negatively regulated MMP2 expression.

Let-7b and let-7g expression in remodeled pulmonary artery are significantly decreased, and the loss of the inhibitory effect of let-7g on c-myc-B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1)-p16 pathway may induce PASMCs proliferation resulting in vascular remodeling in rats with hypoxic pulmonary hypertension.[22] miR-17 improves the functions of the lungs and heart in experimental PH through up-regulating p21 and, therefore, may be used for PH treatment.[23] miR-17 affects the proliferation and apoptosis of PASMCs via regulating mitofusin 2, and thus may serve as a novel target for treating pulmonary arterial hypertension (PAH).[24] These results indicated that hsa-let-7b-3p and hsa-miR-17-5p might be related to the mechanisms of CTEPH.

In this study, increased expression of hsa-miR-3202 and hsa-miR-665 was detected in CTEPH patients, and hsa-miR-3202 was predicted to be associated with the function “Insulin secretion”. It has been reported that miR-3202 overexpression may have a protective effect on epithelial cells by inhibiting Fas-apoptotic inhibitory molecule 2 (FAIM2), and thus miR-3202 may be considered as a promising marker of smoking-related chronic obstructive pulmonary disease (COPD).[25] Similarly, miR-3202 is implicated in the proliferation and apoptosis of epithelial cells in high-glucose medium via targeting FAIM2.[26] Interestingly, it has been revealed that hyperglycemia and insulin resistance account for the development of PAH via regulating the proliferation of epithelial or smooth muscle cells (SMCs) and fibrosis.[27] Thus, we hypothesized that miR-3202 might be related to the development of CTEPH via participating in insulin resistance. In addition, it has been reported that miR-665 overexpression can promote the proliferation and migration of vascular SMCs through regulating myocyte enhancer factor 2D and fibroblast growth factor 9.[28] Notably, the proliferation of pulmonary artery SMCs is a key factor for CTEPH development.[29] Collectively, hsa-miR-3202 and hsa-miR-665 might play essential roles in the pathogenesis of CTEPH.

MMP2, a Zn+2-dependent endopeptidase, plays a role in the degradation of proteins in the extracellular matrix, which is implicated in many BPs such as oncogenesis, regulation of vascularization, and wound healing.[30] MMP2/tissue inhibitor of metalloprotease 4 ratio is found to be an indicator of right ventricular function, disease severity, and survival prognosis, which may contribute to the progression of idiopathic PAH.[31,32] Our RT-PCR results showed that MMP2 was up-regulated in CTEPH patients compared with controls. Consistently, increased expression of MMP2 is found in CTEPH patients, showing that its dysregulation is involved in pulmonary vascular remodeling.[33] In addition, we found a significant decrease in the expression of miR-106b-5p in CTEPH patients, and the targeting of the 3’UTR of MMP2 was confirmed by luciferase reporter assay. Reportedly, the progressive decline of plasma miR-106b may reflect the changes occurring in the patients with COPD, indicating that miR-106b may be correlated with the development and progression of COPD.[34] Moreover, downregulation of miR-106b may promote the invasion and motility of breast cancer cells by mediating upregulation of MMP2.[35] Notably, the correlation of miR-106b-5p and MMP2 in CTEPH has not been reported. Thus, we suggested that downregulation of miR-106b-5p might be implicated in the development of CTEPH via upregulation of MMP2. However, our study is limited by lacking of the expression verification of MMP2 in the presence of a miR-106b-5p mimic or inhibitor, and following functional experiments.

In conclusion, several dysregulated miRNAs (including hsa-let-7b-3p, hsa-miR-17-5p, hsa-miR-665, and hsa-miR-3202) might account for the pathogenesis of CTEPH. In addition, hsa-miR-106b-5p may be involved in the development of CTEPH via negatively regulating MMP2 expression. However, more experiments are still necessary to explore and confirm the roles of these miRNAs and genes in CTEPH.

Click here for additional data file.

Supplemental material, sj-pdf-1-pul-10.1177_2045894020928300 for hsa-miR-106b-5p participates in the development of chronic thromboembolic pulmonary hypertension via targeting matrix metalloproteinase 2 by Ran Miao, Xingbei Dong, Juanni Gong, Ying Wang, Xiaojuan Guo, Yidan Li, Min Liu, Jun Wan, Jifeng Li, Suqiao Yang, Wang Wang, Tuguang Kuang, Jiuchang Zhong, Zhenguo Zhai and Yuanhua Yang in Pulmonary Circulation

Click here for additional data file.

Supplemental material, sj-pdf-2-pul-10.1177_2045894020928300 for hsa-miR-106b-5p participates in the development of chronic thromboembolic pulmonary hypertension via targeting matrix metalloproteinase 2 by Ran Miao, Xingbei Dong, Juanni Gong, Ying Wang, Xiaojuan Guo, Yidan Li, Min Liu, Jun Wan, Jifeng Li, Suqiao Yang, Wang Wang, Tuguang Kuang, Jiuchang Zhong, Zhenguo Zhai and Yuanhua Yang in Pulmonary Circulation

Click here for additional data file.

Supplemental material, sj-pdf-3-pul-10.1177_2045894020928300 for hsa-miR-106b-5p participates in the development of chronic thromboembolic pulmonary hypertension via targeting matrix metalloproteinase 2 by Ran Miao, Xingbei Dong, Juanni Gong, Ying Wang, Xiaojuan Guo, Yidan Li, Min Liu, Jun Wan, Jifeng Li, Suqiao Yang, Wang Wang, Tuguang Kuang, Jiuchang Zhong, Zhenguo Zhai and Yuanhua Yang in Pulmonary Circulation

Click here for additional data file.

Supplemental material, sj-pdf-4-pul-10.1177_2045894020928300 for hsa-miR-106b-5p participates in the development of chronic thromboembolic pulmonary hypertension via targeting matrix metalloproteinase 2 by Ran Miao, Xingbei Dong, Juanni Gong, Ying Wang, Xiaojuan Guo, Yidan Li, Min Liu, Jun Wan, Jifeng Li, Suqiao Yang, Wang Wang, Tuguang Kuang, Jiuchang Zhong, Zhenguo Zhai and Yuanhua Yang in Pulmonary Circulation